Aitor Villate

December 28, 2024

Uncovering metabolic dysregulation in schizophrenia and cannabis use disorder through untargeted plasma lipidomics

Abstract Cannabis use disorder affects up to 42% of individuals with schizophrenia, correlating with earlier onset, increased positive symptoms, and…

March 7, 2023

Chitosan-Coated Alginate Microcapsules of a Full-Spectrum Cannabis Extract: Characterization, Long-Term Stability and In Vitro Bioaccessibility

Abstract Cannabinoids present in Cannabis sativa are increasingly used in medicine due to their therapeutic potential. Moreover, the synergistic interaction…

September 14, 2022

Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients

Abstract Cannabis use disorder is frequent in schizophrenia patients, and it is associated with an earlier age of onset and…